Axsome Therapeutics
AXSM
187 hedge funds and large institutions have $1.15B invested in Axsome Therapeutics in 2022 Q3 according to their latest regulatory filings, with 40 funds opening new positions, 69 increasing their positions, 48 reducing their positions, and 23 closing their positions.
74% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 23
44% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 48
39% more capital invested
Capital invested by funds: $827M → $1.15B (+$319M)
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
8.25% more ownership
Funds ownership: 55.5% → 63.74% (+8.2%)
7% more funds holding
Funds holding: 174 → 187 (+13)
0% more call options, than puts
Call options by funds: $114M | Put options by funds: $113M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$76.9M |
| 2 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
+$47.7M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$28.8M |
| 4 |
PBA
Paradigm Biocapital Advisors
New York
|
+$26M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$15.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$31.7M |
| 2 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$16M |
| 3 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
-$13.5M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$7.85M |
| 5 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$7.64M |
AXSM Hedge Fund Activity: Q3 2022 in Review
187 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Axsome Therapeutics (AXSM) for Q3 2022, worth a combined $1.15B — up 39% from $827M a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new AXSM positions and 23 closed out — a net gain of 17 holders — while 69 added to existing stakes and 48 trimmed.
The largest buyer was Avidity Partners Management, opening a new position worth an estimated $76.9M. The largest seller was Adage Capital Partners, cutting an estimated $31.7M.
- 187 institutional investors held Axsome Therapeutics (AXSM) as of Q3 2022, up from 174 in Q2 2022.
- Funds reported $1.15B of Axsome Therapeutics stock for Q3 2022, up 39% quarter-over-quarter.
- 40 funds opened new Axsome Therapeutics positions in Q3 2022 and 23 closed out, a net change of +17 holders.
- The largest Axsome Therapeutics buyer in Q3 2022 was Avidity Partners Management, an estimated $76.9M added.
- The largest Axsome Therapeutics seller in Q3 2022 was Adage Capital Partners, an estimated $31.7M sold.
Based on aggregated 13F filings for Q3 2022.